59 related articles for article (PubMed ID: 19875174)
1. Accumulation of Eu3+ chelates in cells expressing or not P-glycoprotein: implications for blood-brain barrier crossing.
Darghal N; Garnier-Suillerot A; Bouchemal N; Gras G; Geraldes CF; Salerno M
J Inorg Biochem; 2010 Jan; 104(1):47-54. PubMed ID: 19875174
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
3. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
4. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes.
Nakagawa S; Deli MA; Kawaguchi H; Shimizudani T; Shimono T; Kittel A; Tanaka K; Niwa M
Neurochem Int; 2009; 54(3-4):253-63. PubMed ID: 19111869
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
[TBL] [Abstract][Full Text] [Related]
6. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
[TBL] [Abstract][Full Text] [Related]
7. Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development.
Virgintino D; Errede M; Girolamo F; Capobianco C; Robertson D; Vimercati A; Serio G; Di Benedetto A; Yonekawa Y; Frei K; Roncali L
J Neuropathol Exp Neurol; 2008 Jan; 67(1):50-61. PubMed ID: 18091560
[TBL] [Abstract][Full Text] [Related]
8. Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia.
Bebawy M; Chetty M
Bioessays; 2008 Feb; 30(2):183-8. PubMed ID: 18200566
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier.
Steuer H; Jaworski A; Elger B; Kaussmann M; Keldenich J; Schneider H; Stoll D; Schlosshauer B
Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):1047-53. PubMed ID: 15728564
[TBL] [Abstract][Full Text] [Related]
10. Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development.
Marchi N; Guiso G; Caccia S; Rizzi M; Gagliardi B; Noé F; Ravizza T; Bassanini S; Chimenti S; Battaglia G; Vezzani A
Neurobiol Dis; 2006 Dec; 24(3):429-42. PubMed ID: 17027274
[TBL] [Abstract][Full Text] [Related]
11. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
Grauer MT; Uhr M
J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
14. Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques.
Li Q; Min J; Ahn YH; Namm J; Kim EM; Lui R; Kim HY; Ji Y; Wu H; Wisniewski T; Chang YT
Chembiochem; 2007 Sep; 8(14):1679-87. PubMed ID: 17705341
[TBL] [Abstract][Full Text] [Related]
15. Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model.
Vautier S; Milane A; Fernandez C; Buyse M; Chacun H; Farinotti R
Neurosci Lett; 2008 Sep; 442(1):19-23. PubMed ID: 18598736
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
[TBL] [Abstract][Full Text] [Related]
17. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
18. Functional expression and localization of P-glycoprotein at the blood brain barrier.
Bendayan R; Lee G; Bendayan M
Microsc Res Tech; 2002 Jun; 57(5):365-80. PubMed ID: 12112443
[TBL] [Abstract][Full Text] [Related]
19. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
20. Ability of carbazole salts, inhibitors of Alzheimer beta-amyloid fibril formation, to cross cellular membranes.
Saengkhae C; Salerno M; Adès D; Siove A; Le Moyec L; Migonney V; Garnier-Suillerot A
Eur J Pharmacol; 2007 Mar; 559(2-3):124-31. PubMed ID: 17291491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
